Redhill Biophrma ADR (RDHL)

$1.07 0.00 (N/A)
Market Cap 3.56M
Revenue (ttm) 8.04M
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -102.86%
Debt to Equity Ratio 0.00
Volume 62,300
Avg Vol 2,315,258
Day's Range N/A - N/A
Shares Out 3.33M
Stochastic %K 9%
Beta 4.56
Analysts Strong Buy
Price Target $40.00

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 541 3131
Fax: 972 3 541 3144
Address:
21 Ha’arba’a Street, Tel Aviv, Israel
newbulloh2
newbulloh2 Nov. 14 at 9:34 PM
$DFLI + $RDHL same 1.12 value!!
0 · Reply
newbulloh2
newbulloh2 Nov. 14 at 9:31 PM
$MSPR $RDHL 1.12 value!!!
0 · Reply
Roger73PF
Roger73PF Nov. 12 at 6:30 PM
$RDHL this stock is strongly undervalued, manipulated... but just my opinion
2 · Reply
DonZulu
DonZulu Nov. 12 at 6:01 PM
$RDHL 6-10$ stock watch in january
0 · Reply
1004yo
1004yo Nov. 11 at 11:03 PM
$RDHL Most of the volume is OTC. Could you explain what this means?
1 · Reply
therealchorris
therealchorris Nov. 11 at 4:05 PM
$RDHL Then the next notice from Nasdaq that they are no longer compliant with the listing rules 🙄 Reverse split, rinse, repeat until no one owns anything.
1 · Reply
Stockking24
Stockking24 Nov. 11 at 3:46 PM
$RDHL there she goes like clock work soon under $1 lol 😂
0 · Reply
Roger73PF
Roger73PF Nov. 11 at 10:45 AM
$RDHL This is a good candidate for a buy out. Even at 10x its current market cap, it would still be a very cheap price for a big pharma company. Honestly, I don't understand
0 · Reply
Stockking24
Stockking24 Nov. 10 at 6:51 PM
$RDHL when bankruptcy? 😂
1 · Reply
therealchorris
therealchorris Nov. 10 at 6:48 PM
$RDHL You have to ask yourself why no one bought them already. The price for all shares is less than the Xmas party bill at a big pharma.
0 · Reply
Latest News on RDHL
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Nov 4, 2025, 9:30 AM EST - 10 days ago

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Oct 22, 2025, 4:50 PM EDT - 23 days ago

RedHill Biopharma Receives Nasdaq Staff Determination Notification

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Oct 20, 2025, 9:05 AM EDT - 25 days ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

CPIX

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

Oct 6, 2025, 8:00 AM EDT - 5 weeks ago

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Sep 29, 2025, 7:00 AM EDT - 6 weeks ago

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

Sep 5, 2025, 7:00 AM EDT - 2 months ago

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

Aug 20, 2025, 9:00 AM EDT - 3 months ago

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

Aug 18, 2025, 9:00 AM EDT - 3 months ago

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 21, 2025, 9:00 AM EDT - 4 months ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Jul 1, 2025, 12:00 PM EDT - 4 months ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025, 7:00 AM EDT - 6 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025, 7:00 AM EDT - 7 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 28, 2025, 7:03 AM EDT - 7 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 17, 2025, 4:01 PM EDT - 7 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 16, 2025, 7:00 AM EDT - 7 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Apr 10, 2025, 7:48 AM EDT - 7 months ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 18, 2025, 7:00 AM EDT - 8 months ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Mar 12, 2025, 7:00 AM EDT - 8 months ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 27, 2025, 7:00 AM EST - 9 months ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 25, 2025, 7:00 AM EST - 9 months ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Feb 4, 2025, 7:00 AM EST - 10 months ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Jan 21, 2025, 7:00 AM EST - 10 months ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 10, 2024, 7:00 AM EST - 1 year ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Dec 2, 2024, 7:00 AM EST - 1 year ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 28, 2024, 7:00 AM EDT - 1 year ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 14, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Oct 1, 2024, 7:00 AM EDT - 1 year ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 30, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 9, 2024, 7:00 AM EDT - 1 year ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Sep 3, 2024, 7:00 AM EDT - 1 year ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 29, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces First Half 2024 Business Highlights

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 26, 2024, 7:00 AM EDT - 1 year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Talicia® Launched in the United Arab Emirates

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Talicia® Launched in the United Arab Emirates

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

Aug 19, 2024, 8:56 AM EDT - 1 year ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 19, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 16, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jul 9, 2024, 8:00 AM EDT - 1 year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

Jun 3, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

May 6, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 24, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 8, 2024, 9:23 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Apr 2, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Mar 11, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Mar 5, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

GILD

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Feb 20, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

AMGN GILD

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

Jan 26, 2024, 12:46 PM EST - 1 year ago

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

newbulloh2
newbulloh2 Nov. 14 at 9:34 PM
$DFLI + $RDHL same 1.12 value!!
0 · Reply
newbulloh2
newbulloh2 Nov. 14 at 9:31 PM
$MSPR $RDHL 1.12 value!!!
0 · Reply
Roger73PF
Roger73PF Nov. 12 at 6:30 PM
$RDHL this stock is strongly undervalued, manipulated... but just my opinion
2 · Reply
DonZulu
DonZulu Nov. 12 at 6:01 PM
$RDHL 6-10$ stock watch in january
0 · Reply
1004yo
1004yo Nov. 11 at 11:03 PM
$RDHL Most of the volume is OTC. Could you explain what this means?
1 · Reply
therealchorris
therealchorris Nov. 11 at 4:05 PM
$RDHL Then the next notice from Nasdaq that they are no longer compliant with the listing rules 🙄 Reverse split, rinse, repeat until no one owns anything.
1 · Reply
Stockking24
Stockking24 Nov. 11 at 3:46 PM
$RDHL there she goes like clock work soon under $1 lol 😂
0 · Reply
Roger73PF
Roger73PF Nov. 11 at 10:45 AM
$RDHL This is a good candidate for a buy out. Even at 10x its current market cap, it would still be a very cheap price for a big pharma company. Honestly, I don't understand
0 · Reply
Stockking24
Stockking24 Nov. 10 at 6:51 PM
$RDHL when bankruptcy? 😂
1 · Reply
therealchorris
therealchorris Nov. 10 at 6:48 PM
$RDHL You have to ask yourself why no one bought them already. The price for all shares is less than the Xmas party bill at a big pharma.
0 · Reply
GoStros
GoStros Nov. 10 at 6:25 PM
$RDHL don't they have good product and may be a future buy out candidate
0 · Reply
Pennystockmadness
Pennystockmadness Nov. 10 at 4:11 PM
$RDHL break $1.10 and $1.15+ in play for today!!!!
0 · Reply
thedavidsonny
thedavidsonny Nov. 10 at 2:53 AM
$RDHL Monday is gonna be a Great day
1 · Reply
Pennystockmadness
Pennystockmadness Nov. 9 at 6:08 PM
$RDHL any updates on grants, trials or government contracts will send this flying!!!
0 · Reply
StockFlips
StockFlips Nov. 8 at 11:44 AM
$NNVC $YGMZ $RDHL 🔥🪽
0 · Reply
Mattcriger
Mattcriger Nov. 7 at 6:52 PM
$RDHL the naked shorting should be immediately investigated.
0 · Reply
SuperBusa
SuperBusa Nov. 7 at 3:44 PM
$RDHL
0 · Reply
Kpip
Kpip Nov. 7 at 2:07 PM
$RDHL GLTA. I took my 25% loss. Time to move on.
0 · Reply
Stockking24
Stockking24 Nov. 7 at 1:54 PM
$RDHL NEW LOWS INCOMIMG…
1 · Reply
Michl2000
Michl2000 Nov. 7 at 1:28 PM
$RDHL probably below 1$ in a couple of days, maybe already today
0 · Reply
Pennystockmadness
Pennystockmadness Nov. 7 at 11:42 AM
$RDHL day 3 of green???
0 · Reply
Guanabo498
Guanabo498 Nov. 7 at 11:12 AM
$RDHL $ 1.50
0 · Reply